Skip to main navigation Skip to search Skip to main content

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

  • EV-302 Trial Investigators
  • Queen Mary University of London
  • Hospital Universitario Virgen del Rocio
  • Cleveland Clinic Foundation
  • Klinikum Stuttgart
  • St. Marianna University School of Medicine
  • Johns Hopkins University
  • Memorial Sloan-Kettering Cancer Center
  • AZ Maria Middelares
  • University of Antwerp
  • Yonsei University
  • Hospital Universitario 12 de Octubre
  • University Eye Clinic
  • Veterans General Hospital-Taichung Taiwan
  • Ministry of Health, Turkey
  • University of California at Irvine
  • Gustave Roussy
  • Centre Léon Bérard
  • Hospital Universitario Marques de Valdecilla
  • University of California at Los Angeles
  • Seagen Inc.
  • Astellas Pharma Inc.
  • Merck
  • Netherlands Cancer Institute

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science